DBV's peanut allergy patch is finally under FDA review; Ritter swallows bitter pill to explore strategic alternatives
→ DBV Technologies $DBVT, which withdrew its application to market its peanut allergy patch late last year, essentially enabling rival Aimmune $AIMT to
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
